title: Modulation of glycoconjugate biosynthesis by 5-hexyl-2'-deoxyuridine in highly metastatic Lewis lung carcinoma cells.
abstract: The mechanism of action of 5-hexyl-2-'deoxyuridine (HUdR), a compound with antitumor activity, has been investigated in the HM cell lines derived from the highly metastatic variant of Lewis lung carcinoma (3LL-HH). It was shown that this pyrimidine analog did not inhibit the biosynthesis of nucleotides but modified the biosynthesis of glycoconjugates. The incorporation of [14C]-glucosamine into cytoplasmic glycoconjugates [glycosaminoglycan (GAG), glycolipid (GL), glycoprotein (GP), neutral polysaccharide (NP)] decreased to a similar level. The [14C]-glucosamine derived radioactivity was reduced to about 60-70% of the untreated controls in the presence of 15 micrograms/ml HUdR, which caused no inhibition of cell proliferation. These results might be explained by the reduced conversion of glucosamine into uridine-5'-diphospho-hexosamine. As more reduction was observed in the glucosamine labeling of glycoconjugates in nuclei and extracellular compartment, it may be conceivable that the intracellular transport of certain glycoconjugates (GAG, GP) is also affected by HUdR. In the extracellular compartment the reduced level of GAG labeling was the most apparent change. However, at a higher concentration of HUdR (75 micrograms/ml) there was a higher radioactivity in the combined GL + GP fraction. Using [35S]-labeling, the GAG fractions also showed a decreased radioactivity but only at the concentration of 75 micrograms/ml HUdR.
authors.affiliation: Joint Research Organization of the Hungarian Academy of Sciences, Budapest.
authors.forename: G
authors.initials: G
authors.lastname: Pogány
authors.forename: A
authors.initials: A
authors.lastname: Jeney
authors.forename: J
authors.initials: J
authors.lastname: Timár
authors.forename: J
authors.initials: J
authors.lastname: Major
authors.forename: K
authors.initials: K
authors.lastname: Lapis
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D002460:Cell Line; D002467:Cell Nucleus / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003593:Cytoplasm / Q000378:metabolism; D003857:Deoxyuridine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006001:Glycoconjugates / Q000096:biosynthesis* / Q000302:isolation & purification / Q000493:pharmacokinetics; D006017:Glycolipids / Q000096:biosynthesis; D006023:Glycoproteins / Q000096:biosynthesis; D006025:Glycosaminoglycans / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000964:Antimetabolites, Antineoplastic; D006001:Glycoconjugates; D006017:Glycolipids; D006023:Glycoproteins; D006025:Glycosaminoglycans; C064952:5-hexyl-2'-deoxyuridine; D003857:Deoxyuridine